Darwin AG to Showcase Personalized Health Strategy at Major German Investment Conferences

Darwin AG will participate in two significant capital markets conferences during spring 2026, presenting its equity story and corporate developments to both retail and institutional investors. The company's dual-conference approach demonstrates strategic outreach across different investor segments while emphasizing its position in the precision health sector. At the Invest conference in Stuttgart from April 17-18, 2026, CEO Dr. Daniel Wallerstorfer will present under the theme "Invest in the Future of Precision Health," focusing on how personalized solutions are shaping healthcare markets. This presentation targets retail investors at Messe Stuttgart, where visitors can meet management at Hall 4, Booth 4E32 to learn about personalized health products. Further information about Invest can be found at https://darwin-biotech.com/.

The company will then present at the Equity Forum's 2026 Spring Conference in Frankfurt from May 11-12, 2026, a MiFID II-compliant event for institutional investors, analysts, and financial journalists. This presentation will include a corporate update, audited financial results for 2025, and operational and strategic outlooks, coinciding with the publication of the 2025 consolidated financial statements in the Annual Report on May 12, 2026. Following the presentation, Dr. Wallerstorfer will be available for one-on-one meetings scheduled through the conference website. More information about the 2026 German Spring Conference can be found at https://darwin-biotech.com/.

These conference appearances matter because they represent critical touchpoints for investor communication during a period of financial disclosure and strategic positioning. The timing of the Equity Forum presentation immediately following the release of annual financial results suggests coordinated messaging to professional investors about the company's performance and future direction. Meanwhile, the Invest conference presentation to retail investors indicates broader market education efforts about personalized healthcare investment opportunities. The company's focus on precision health aligns with growing investor interest in healthcare innovation and personalized medicine, sectors experiencing increased capital allocation globally.

The implications of these presentations extend beyond routine investor relations, potentially influencing market perception and valuation ahead of key financial disclosures. By engaging both retail and institutional audiences, Darwin AG demonstrates comprehensive investor outreach while addressing different information needs and investment horizons. The company's emphasis on personalized health solutions through genetic analysis positions it within expanding healthcare markets where tailored treatments and preventive approaches gain prominence. These conferences provide platforms for articulating how genetic-based personalization creates competitive advantages and addresses evolving healthcare demands, potentially impacting investment decisions and analyst coverage in the biotechnology and healthcare sectors.